Gastrointestinal
Drugs Advisory Committee
QUESTIONS
June 26, 2003
1.
Appropriate
patients for PHOTOFRIN PDT
a)
The diagnosis
of high-grade dysplasia was confirmed by the Central Reference Laboratory in
about 50% of patients with that diagnosis. Discuss what impact the inability to
confirm a high-grade dysplasia diagnosis has on the use of PHOTOFRIN. Provide
recommendations to ensure use of this therapy in the appropriate population.
b)
Should the
diagnosis of high-grade dysplasia be confirmed by a reference laboratory of
acknowledged experts before PHOTOFRIN PDT is undertaken?
2.
Efficacy
a)
Do the
applicant’s data demonstrate efficacy of PHOTOFRIN PDT in complete ablation of
high-grade dysplasia in Barrett’s esophagus?
b)
Is a 2-year
follow-up period adequate to demonstrate cancer risk reduction in high-grade
dysplasia patients treated with PHOTOFRIN PDT?
c)
How frequently
should patients who have undergone PHOTOFRIN PDT be monitored by esophagoscopy?
3.
Safety:
Is
the safety profile of PHOTOFRIN PDT acceptable?
4.
Follow-up
The
applicant is continuing to collect patient follow-up data in the PHO BAR 02
study for an additional 3 years. PHO BAR 01 and PHO BAR 02 taken together will
provide a maximum of 5 years of follow-up for patients in the 2 arms of the
study. Is this adequate to demonstrate cancer risk reduction in high-grade
dysplasia patients?